ClinicalTrials.gg
RecruitingNCT07552454Updated Apr 27, 2026

Picankibart in Palmoplantar Pustulosis

An interventional study of Picankibart in Palmoplantar Pustulosis, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
135th of 182
60 · median 171
Started
2026
with 17 others
No phase
20 of 206
7 open now
Primary completion
2027-10
later than 53 of 65 live
Registered
192nd of 206
by date
Lead sponsor
9 of 206
Xijing Hospital

Among the 206 studies in Psoriasis with a site in China, this one is the 135th largest by planned enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2026, is one of 20 with no phase, reaches primary completion later than 53 of the 65 other live ones, and was the 192nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

  1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects.
  2. Study Subjects

Inclusion Criteria

  1. Aged 18-65 years, regardless of gender.
  2. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology.
  3. Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.
  4. Considered suitable for treatment with Picankibart as assessed by the clinician.
  5. Voluntarily participate in the study and provide written informed consent.

Exclusion Criteria

  1. Patients with active hepatitis B, hepatitis C, or tuberculosis.
  2. Pregnant patients or those planning pregnancy within 6 months.
  3. Subjects unable to comply with follow-up as required by the study protocol.
  4. Other conditions deemed unsuitable for this study.

Withdrawal Criteria

  1. Subjects may withdraw from the study at any time for any reason.
  2. Occurrence of a serious adverse event or intolerable adverse event.
  3. Development of any item listed in the exclusion criteria during the study.
  4. The investigator may decide subject withdrawal for medical reasons.
03

Conditions studied

  • Palmoplantar Pustulosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years, regardless of gender. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology.

Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.

Considered suitable for treatment with picankibart as assessed by the clinician.

Voluntarily participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients with active , , or tuberculosis. Pregnant patients or those planning pregnancy within 6 months. Subjects unable to comply with follow-up as required by the study protocol. Other conditions deemed unsuitable for this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Picankibart in Palmoplantar Pustulosis

    Drug: Picankibart

Interventions

  • Induction phase: Picankibart 200 mg administered subcutaneously at Weeks 0, 4, and 8. Maintenance phase: Picankibart 100 mg administered subcutaneously at Weeks 20, 32, and 44.

06

What researchers measure

Primary outcomes

  1. Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)

    Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)

    Time frame: 16 Week

  2. Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)

    Time frame: 16 Week

07

Study locations

1 of 1 sites recruiting
  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China
    Xi'an, Shaanxi 710032, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 18 months is below that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552454
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Shuai Shao
Contact
2269744794@qq.com
8619249282690

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Picankibart

Start the discussion